Cytokinetics: Small Label Differences With Big Commercial Stakes [Seeking Alpha]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Seeking Alpha
ORZO's label offers subtle practical advantages over CAMZYOS, notably flexible dosing, enhancing real-world usability. CYTK management targets 50% preference share and increased category penetration to mid-high 20% by the end of 2026, which implies gradual adoption and reliance on assistance programs. CYTK's $1.25B cash position supports a three-year runway, but near-term profitability is unlikely as SG&A costs rise during MYQORZO's commercialization. Marvin Samuel Tolentino Pineda/iStock via Getty Images Overview Cytokinetics, Incorporated's ( CYTK ) stock is up over 40% since my last Buy rating in September. Ahead of its December PDUFA date, the focus was on aficamten's differentiation compared to Bristol-Myers Squibb's ( This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Cytokinetics (NASDAQ:CYTK) was given a new $84.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Cytokinetics (NASDAQ:CYTK) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Cytokinetics (NASDAQ:CYTK) was given a new $83.00 price target on by analysts at Leerink Partners.MarketBeat
- Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript [Seeking Alpha]Seeking Alpha
- Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Holley Inc. (NYSE: HLLY); Molina Healthcare, Inc. (NYSE: MOH); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your BehalfGlobeNewswire
CYTK
Earnings
- 11/5/25 - Miss
CYTK
Sec Filings
- 12/22/25 - Form 144
- 12/19/25 - Form 8-K
- 12/16/25 - Form 4
- CYTK's page on the SEC website